
Will GoodRX Stock Bounce Back?
GoodRX (NASDAQ:GDRX) tracks prescription drug prices and its model was…
Date | Quarter | Revenue Forecast | Actual Revenue | Reported EPS | Consensus EPS | Beat/Miss |
---|---|---|---|---|---|---|
09/30/2025 | Q3 | $23.6B | -- | -- | -- | -- |
08/01/2025 | Q2 | $25.8B | -- | -- | -- | -- |
05/01/2025 | Q1 | $23.4B | -- | -- | -- | -- |
02/04/2025 | Q4 | $25.6B | -- | -- | -- | -- |
11/01/2024 | Q3 | $23.3B | -- | -- | -- | -- |
08/01/2024 | Q2 | $21.1B | $24.6B | $11.85 | -- | -- |
05/01/2024 | Q1 | $21.7B | $22.4B | $15.13 | -- | -- |
02/13/2024 | Q4 | $21.8B | $24.5B | $12.16 | -- | -- |
09/30/2023 | Q3 | $22.1B | $22.3B | $9.33 | -- | -- |
06/30/2023 | Q2 | $23.6B | $22.9B | $12.12 | -- | -- |
03/31/2023 | Q1 | -- | $24.8B | $14.26 | -- | -- |
12/31/2022 | Q4 | -- | $25.6B | $13.74 | -- | -- |
09/30/2022 | Q3 | -- | $26.8B | $12.10 | -- | -- |
06/30/2022 | Q2 | -- | $28.7B | $13.30 | -- | -- |
03/31/2022 | Q1 | -- | $27.3B | $15.01 | -- | -- |
12/31/2021 | Q4 | -- | $27.9B | $12.41 | -- | -- |
09/30/2021 | Q3 | -- | $25.1B | $11.87 | -- | -- |
06/30/2021 | Q2 | -- | $24.3B | $10.57 | -- | -- |
03/31/2021 | Q1 | -- | $21.4B | $7.67 | -- | -- |
12/31/2020 | Q4 | -- | $19.5B | $5.07 | -- | -- |
09/30/2020 | Q3 | -- | $17.5B | $2.66 | -- | -- |
07/31/2020 | Q2 | -- | $17.1B | $3.43 | -- | -- |
05/01/2020 | Q1 | -- | $30.2B | $3.04 | -- | -- |
02/04/2020 | Q4 | -- | $16.4B | $5.35 | -- | -- |
10/30/2019 | Q3 | -- | $16.6B | $5.85 | -- | -- |
07/31/2019 | Q2 | -- | $14.9B | $6.54 | -- | -- |
04/26/2019 | Q1 | -- | $17.7B | $3.35 | -- | -- |
02/01/2019 | Q4 | -- | $16B | $6.49 | -- | -- |
11/09/2018 | Q3 | -- | $14.9B | $5.39 | -- | -- |
08/02/2018 | Q2 | -- | $14.3B | $6.24 | -- | -- |
05/08/2018 | Q1 | -- | $11.4B | $2.22 | -- | -- |
02/02/2018 | Q4 | -- | $11.1B | $6.95 | -- | -- |
11/02/2017 | Q3 | -- | $10.9B | $6.51 | -- | -- |
08/03/2017 | Q2 | -- | $10.6B | $5.65 | -- | -- |
05/09/2017 | Q1 | -- | $10.4B | $3.75 | -- | -- |
02/08/2017 | Q4 | -- | $10.5B | $5.54 | -- | -- |
11/02/2016 | Q3 | -- | $9.9B | $3.31 | -- | -- |
08/03/2016 | Q2 | -- | $9.4B | $3.16 | -- | -- |
03/31/2016 | Q1 | -- | $9.4B | -$10.55 | -- | -- |
12/31/2015 | Q4 | -- | $9.7B | $0.17 | -- | -- |
09/30/2015 | Q3 | -- | $9.9B | $1.54 | -- | -- |
Mitsui & reported $24.6B worth of top line sales in its most recent quarter.
Mitsui & announced earnings per share of $11.85 which represents a beat of analyst forecast a -- per share.
Mitsui & reported $2.2B that represents $14.96 per share over the last quarter.
Mitsui &'s earnings are forecast to grow from $40.24 per share to -- per share next year representing an increase of --.
Mitsui &'s next earnings date is August 1, 2025.
Signup to receive the latest stock alerts
GoodRX (NASDAQ:GDRX) tracks prescription drug prices and its model was…
Freeport-McMoRan (NYSE:FCX) is among the world’s largest producers of copper…
Levi Strauss (NYSE:LEVI) is among the oldest clothing brands in…
Market Cap: $4.2T
P/E Ratio: 58x
Market Cap: $3.8T
P/E Ratio: 43x
Market Cap: $3.1T
P/E Ratio: 35x
SharpLink Gaming [SBET] is down 2.6% over the past day.
Exodus Movement [EXOD] is down 4.14% over the past day.
Unity Software [U] is up 7.51% over the past day.